Summary:
Click image to enlargeThe main aim of this study is to evaluate the efficacy of S-217622 versus placebo among participants who are in the subpopulation of participants who were not expected to receive standard-of-care COVID-19 Group A therapy (defined as monoclonal antibody [mAb] treatment or outpatient intravenous [IV] remdesivir).
Between the ages of 18 to 64 years old Must have TESTED POSITIVE for COVID -19 Have had COVID-19 symptoms start within the past 3 days
Qualified Participants May Receive:
COVID-19 Assessment at no cost + Compensation